Skip to main content

Preoperative Labs

This page covers what is worth ordering versus what is reflex before reconstructive urologic and urogynecologic surgery. The high-yield message from the contemporary preoperative-testing literature is that routine "screening" labs in healthy ASA 1–2 patients undergoing low-risk procedures are low-value, drive false-positive workups, and delay care without changing outcomes.[1] This page is the labs-themselves companion to the broader Preoperative Assessment workflow.

When NOT to Order​

Routine preoperative CBC, basic metabolic panel, and coagulation studies in asymptomatic ASA 1–2 patients undergoing low-risk reconstructive procedures (outpatient cystoscopy, simple sling, simple hypospadias revision, urethral dilation, simple cystocele repair) are not recommended by the AAFP, ACP, and Choosing Wisely consensus.[1] Order labs because of a specific clinical indication, not as a reflex tied to surgical scheduling. Abnormal results obtained without indication are usually false positives or clinically irrelevant, but they trigger workups that delay surgery.[1]

The contemporary urogynecologic evidence reinforces this directly. Samsel 2025 retrospectively reviewed 634 urogynecologic surgeries and found that 74% of women had preoperative labs performed, but clinically meaningful lab abnormalities were rare and did not change surgical management in any case — confirming current national guidelines that advise against routine preoperative laboratory testing for pelvic floor disorder surgery in otherwise healthy women.[5] ACOG Practice Bulletin No. 214 (Pelvic Organ Prolapse) correspondingly does not recommend routine bloodwork beyond what is indicated by comorbidities.[6]

The framework below is organized around indications, not procedures.

Section 1 — Complete Blood Count (CBC)​

Indicated when:

  • Major reconstructive procedures with anticipated significant blood loss — radical cystectomy with urinary diversion, complex multistage urethroplasty with flap, abdominal sacrocolpopexy, gracilis-flap reconstruction for rectourethral fistula, vesicovaginal fistula repair after radiation
  • Patients on testosterone replacement therapy (TRT) — monitor for erythrocytosis. Hematocrit >54% on therapy mandates discontinuation; baseline Hct >48% is a relative contraindication to initiation. Recheck at 3 and 6 months and annually thereafter[2]
  • Chronic hematuria — quantify anemia before reconstruction
  • Post-chemotherapy patients undergoing cystectomy or upper-tract reconstruction — NCCN recommends CBC and CMP every 3–6 months in year 1[3]
  • Known myelodysplasia, hemoglobinopathy, or chronic kidney disease

Skip when: Routine outpatient cystoscopy, simple midurethral sling, simple distal hypospadias repair, urethral dilation, or office-based procedures in ASA 1–2 patients with no symptoms of anemia.

Section 2 — Coagulation Studies (PT/INR, aPTT)​

Indicated when:

  • Personal or family history suggesting a bleeding disorder
  • Active anticoagulant use (warfarin baseline INR; DOACs do not require routine PT/PTT but consider anti-Xa if recent dose timing is unclear)
  • Liver disease, malnutrition, or malabsorptive states (post-bariatric, short gut, ileal-conduit long-standing)
  • Recent heparin or LMWH bridging
  • Severe systemic illness or sepsis

Skip when: Healthy ASA 1–2 patients with no bleeding history. The AAFP and ACP explicitly recommend against reflex PT/aPTT before noncardiac surgery in unselected patients.[1]

For perioperative anticoagulation timing and reversal strategy, see Antithrombotic Therapy and Anticoagulation Reversal.

Section 3 — Glucose / HbA1c​

HbA1c is the more durable preoperative measure because it reflects 3-month glycemic control and is not perturbed by perioperative stress hyperglycemia.[4]

Indicated when:

  • Known diabetes — confirm current control before elective major reconstruction
  • Screening before major surgery in patients with risk factors: BMI ≥30, strong family history, glycosuria on UA, prior gestational diabetes, polycystic ovary syndrome
  • Refractory recurrent UTI, voiding dysfunction, or NLUTD presentations where occult diabetes is on the differential

Practical thresholds. Poorly controlled diabetes (HbA1c >8%) elevates surgical-site infection and wound-healing-failure risk and is a reasonable trigger to defer elective reconstruction until optimization is achieved.[1][4] Diabetic patients also have substantially higher rates of recurrent UTI, voiding dysfunction, neurogenic-pattern bladder dysfunction, and impaired anastomotic healing — all directly relevant to reconstructive-urologic outcomes.

Guideline targets and timing. The ADA 2026 Standards of Care set a preoperative HbA1c goal of <8% when feasible without delaying urgent surgery.[7] The 2024 AHA/ACC Perioperative Cardiovascular Guideline assigns a Class 2a recommendation that preoperative HbA1c testing is reasonable if not obtained within the prior 3 months, while noting that there is no evidence that deferring surgery for better glycemic control improves cardiovascular outcomes.[8] The Endocrine Society similarly endorses a target HbA1c <8% for hospitalized patients.[9]

Glycosuria on routine UA should prompt formal diabetes evaluation with HbA1c — particularly relevant in reconstructive practice where occult diabetes is often unmasked during workups for refractory recurrent UTI, voiding dysfunction, or impaired healing after prior surgery.

SGLT2 inhibitor caveat. SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) must be discontinued 3–4 days before surgery to reduce the risk of perioperative euglycemic diabetic ketoacidosis.[8]

Skip when: ASA 1–2 patients with no diabetes risk factors undergoing low-risk procedures.

For broader diabetes optimization (insulin holds, SGLT2 inhibitor euglycemic DKA risk, sliding scale on the day of surgery), see the Preoperative Assessment — Diabetes page.

Section 4 — BMP / CMP​

For routine general preoperative use (distinct from the lifelong diversion-specific surveillance covered at Renal Function & Metabolic Surveillance):

Indicated when:

  • Chronic kidney disease (any stage) — establishes baseline creatinine and electrolytes
  • On diuretics, ACE inhibitors, or ARBs — risk for hypokalemia, hyperkalemia, or pre-renal AKI
  • On medications with renal clearance (gabapentin, vancomycin, LMWH, methotrexate) requiring dose adjustment
  • Major surgery with anticipated significant fluid shifts (cystectomy, large flap reconstruction, prolonged operative time)
  • Adrenal insufficiency or chronic corticosteroid use (electrolyte and glucose baseline)

Skip when: Healthy ASA 1–2 patients undergoing outpatient or short-stay procedures, no medications requiring renal monitoring.[1]

Section 5 — Type and Screen / Type and Crossmatch​

Match the order to anticipated blood-loss volume, not to procedure category by reflex:

  • Type and screen: radical cystectomy with urinary diversion, complex urethroplasty with flap, large pedicled or free flap reconstruction (gracilis, VRAM, ALT), open sacrocolpopexy, complex fistula repair after radiation, augmentation cystoplasty, posterior urethroplasty for PFUI
  • Type and crossmatch (units reserved): patients with known antibodies, patients with low baseline Hgb, anticipated >500 mL blood loss, redo surgery in scarred fields
  • Skip: outpatient endoscopic procedures, simple slings, office-based procedures

Institutional MSBOS (maximum surgical blood ordering schedule) policies operationalize this — confirm local conventions.

When to Order vs. Skip — Quick Reference​

LabOrder WhenSkip When
CBCMajor reconstruction; chronic hematuria; on TRT; post-chemotherapy cystectomyCystoscopy; simple sling; simple hypospadias in ASA 1–2
PT/INR/aPTTBleeding history; on anticoagulant; liver disease; malabsorptionHealthy ASA 1–2 with no bleeding history
BMP/CMPCKD; on diuretics/ACE-I/ARB; major fluid shifts; chronic steroidsRoutine outpatient procedures in ASA 1–2
HbA1cKnown DM; glycosuria on UA; BMI ≥30 before major surgeryASA 1–2 with no diabetes risk factors
Type & ScreenCystectomy/diversion; complex urethroplasty; large flap; sacrocolpopexyOutpatient endoscopic procedures
Type & CrossmatchKnown antibodies; low baseline Hgb; redo radiated fieldRoutine cases without bleeding-risk features

Reconstruction-Specific Risk Factors That Change the Calculus​

Several patient cohorts seen disproportionately in reconstructive practice deserve more aggressive preoperative laboratory assessment than their ASA class would suggest:

  • Long-standing urinary diversion — chronic metabolic acidosis, hypokalemia, B12 deficiency (ileal segments), hyperchloremic acidosis (colonic segments). See Renal Function & Metabolic Surveillance
  • Spinal cord injury / NLUTD — autonomic dysreflexia risk, baseline renal function reflecting upper-tract status
  • Radiation history — anemia from chronic radiation cystitis bleeding, marrow effects from prior pelvic radiation
  • Testosterone-replacement and gender-affirming hormone therapy patients — Hct surveillance is mandatory[2]
  • Geriatric reconstructive patients — frailty assessment combined with CBC, BMP, and albumin (nutrition surrogate) outperforms age alone for risk stratification
  • Diabetes before urinary diversion — diabetes is an independent risk factor for persistent metabolic acidosis after ileal neobladder (Kim 2016 OR 5.68 at 1 year); see Renal Function & Metabolic Surveillance for the lifelong post-diversion lab framework[10]

See Also​

References​

1. Feely MA, Collins CS, Daniels PR, Kebede EB, Jatoi A, Mauck KF. "Preoperative Testing Before Noncardiac Surgery: Guidelines and Recommendations." Am Fam Physician. 2013;87(6):414–418. https://www.aafp.org/pubs/afp/issues/2013/0315/p414.html

2. Heidelbaugh JJ, Belakovskiy A. "Testosterone Replacement Therapy for Male Hypogonadism." Am Fam Physician. 2024;109(6):543–549. https://www.aafp.org/pubs/afp/issues/2024/0600/testosterone-replacement-therapy.html

3. National Comprehensive Cancer Network. "NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer." Version 1.2026. Surveillance schedule for post-cystectomy patients including CBC and CMP every 3–6 months in year 1. https://www.nccn.org/guidelines/category_1

4. Sacks DB, Arnold M, Bakris GL, et al. "Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus." Diabetes Care. 2023;46(10):e151–e199. doi:10.2337/dci23-0036

5. Samsel T, Ashmore S, Shi J, Kenton K, Mueller M. "Surgical Management of Pelvic Floor Disorders and the Utility of Preoperative Labs." Int Urogynecol J. 2025. doi:10.1007/s00192-025-06307-7

6. American College of Obstetricians and Gynecologists. "Practice Bulletin No. 214: Pelvic Organ Prolapse." Obstet Gynecol. 2019;134(5):e126–e142. doi:10.1097/AOG.0000000000003519

7. American Diabetes Association Professional Practice Committee. "16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026." Diabetes Care. 2026;49(Suppl_1):S339–S355. doi:10.2337/dc26-S016

8. Thompson A, Fleischmann KE, Smilowitz NR, et al. "2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery." J Am Coll Cardiol. 2024;84(19):1869–1969. doi:10.1016/j.jacc.2024.06.013

9. Korytkowski MT, Muniyappa R, Antinori-Lent K, et al. "Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2022;107(8):2101–2128. doi:10.1210/clinem/dgac278

10. Kim KH, Yoon HS, Yoon H, et al. "Risk Factors for Persistent Metabolic Acidosis After Radical Cystectomy and Ileal Orthotopic Neobladder Diversion." World J Urol. 2016;34(8):1193–1199. doi:10.1007/s00345-015-1748-4